Literature DB >> 15908240

The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.

Volker H Haase1.   

Abstract

The von Hippel-Lindau tumor suppressor pVHL plays a critical role in the pathogenesis of familial and sporadic clear cell carcinomas of the kidney and hemangioblastomas of the retina and central nervous system. pVHL targets the oxygen sensitive alpha subunit of hypoxia-inducible factor (HIF) for proteasomal degradation, thus providing a direct link between tumorigenesis and molecular pathways critical for cellular adaptation to hypoxia. Cell type specific gene targeting of VHL in mice has demonstrated that proper pVHL mediated HIF proteolysis is fundamentally important for survival, proliferation and differentiation of many cell types and furthermore, that inactivation of pVHL may, unexpectedly, inhibit tumor growth under certain conditions. Mouse knock out studies have provided novel mechanistic insights into VHL associated tumorigenesis and established a central role for HIF in the development of the VHL phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908240      PMCID: PMC3787877          DOI: 10.1016/j.semcdb.2005.03.006

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  119 in total

1.  Abnormal postpartum renal development and cystogenesis in the bcl-2 (-/-) mouse.

Authors:  C M Sorenson; B J Padanilam; M R Hammerman
Journal:  Am J Physiol       Date:  1996-07

2.  The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis.

Authors:  A R Schoenfeld; T Parris; A Eisenberger; E J Davidowitz; M De Leon; F Talasazan; P Devarajan; R D Burk
Journal:  Oncogene       Date:  2000-11-30       Impact factor: 9.867

3.  Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.

Authors:  Jörn Karhausen; Glenn T Furuta; John E Tomaszewski; Randall S Johnson; Sean P Colgan; Volker H Haase
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

4.  HIF-1alpha induces cell cycle arrest by functionally counteracting Myc.

Authors:  Minori Koshiji; Yukio Kageyama; Erin A Pete; Izumi Horikawa; J Carl Barrett; L Eric Huang
Journal:  EMBO J       Date:  2004-04-08       Impact factor: 11.598

5.  Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells.

Authors:  Christina Warnecke; Zaneta Zaborowska; Jens Kurreck; Volker A Erdmann; Ulrich Frei; Michael Wiesener; Kai-Uwe Eckardt
Journal:  FASEB J       Date:  2004-07-01       Impact factor: 5.191

6.  Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors.

Authors:  Victor R Gordeuk; Adelina I Sergueeva; Galina Y Miasnikova; Daniel Okhotin; Yaroslav Voloshin; Peter L Choyke; John A Butman; Katerina Jedlickova; Josef T Prchal; Lydia A Polyakova
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

7.  Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes.

Authors:  Mangatt P Biju; Aaron K Neumann; Steven J Bensinger; Randall S Johnson; Laurence A Turka; Volker H Haase
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

8.  Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development.

Authors:  David Pfander; Tatsuya Kobayashi; Melissa C Knight; Elazar Zelzer; Denise A Chan; Bjorn R Olsen; Amato J Giaccia; Randall S Johnson; Volker H Haase; Ernestina Schipani
Journal:  Development       Date:  2004-05       Impact factor: 6.868

9.  Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.

Authors:  N de Paulsen; A Brychzy; M C Fournier; R D Klausner; J R Gnarra; A Pause; S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

10.  Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans.

Authors:  Tammie Bishop; Kah Weng Lau; Andrew C R Epstein; Stuart K Kim; Min Jiang; Delia O'Rourke; Christopher W Pugh; Jonathan M Gleadle; Martin S Taylor; Jonathan Hodgkin; Peter J Ratcliffe
Journal:  PLoS Biol       Date:  2004-09-07       Impact factor: 8.029

View more
  34 in total

1.  VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling.

Authors:  Lingchao Chen; Lei Han; Kailiang Zhang; Zhendong Shi; Junxia Zhang; Anling Zhang; Yongzhi Wang; Yijun Song; Yongli Li; Tao Jiang; Peiyu Pu; Chuanlu Jiang; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2012-05-30       Impact factor: 12.300

2.  Vascular biology and pathobiology of the liver: Report of a single-topic symposium.

Authors:  Yasuko Iwakiri; Matthew Grisham; Vijay Shah
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

Review 3.  The von Hippel-Lindau gene: turning discovery into therapy.

Authors:  Peter E Clark; Michael S Cookson
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 4.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

5.  VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis.

Authors:  Tiffany N Seagroves; Danielle L Peacock; Debbie Liao; Luciana P Schwab; Robin Krueger; Charles R Handorf; Volker H Haase; Randall S Johnson
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

6.  Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.

Authors:  Xijuan Liu; Jeremy M Simon; Haibiao Xie; Lianxin Hu; Jun Wang; Giada Zurlo; Cheng Fan; Travis S Ptacek; Laura Herring; Xianming Tan; Mingjie Li; Albert S Baldwin; William Y Kim; Tao Wu; Marc W Kirschner; Kan Gong; Qing Zhang
Journal:  Mol Cell       Date:  2020-02-04       Impact factor: 17.970

7.  Nek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization.

Authors:  Mallikarjun Patil; Navjotsingh Pabla; Shuang Huang; Zheng Dong
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

8.  Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency.

Authors:  Yatrik M Shah; Tsutomu Matsubara; Shinji Ito; Sun-Hee Yim; Frank J Gonzalez
Journal:  Cell Metab       Date:  2009-01-15       Impact factor: 27.287

9.  Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma.

Authors:  Peter E Clark
Journal:  Biologics       Date:  2010-08-09

10.  Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1alpha.

Authors:  Helder André; Teresa S Pereira
Journal:  J Biol Chem       Date:  2008-08-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.